Yarrow Bioscience, Inc. Common Stock
YARW
52 hedge funds and large institutions have $110M invested in Yarrow Bioscience, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 5 closing their positions.
243% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 7
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
2% less funds holding
Funds holding: 53 → 52 (-1)
21% less capital invested
Capital invested by funds: $139M → $110M (-$29.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2M |
| 2 |
BlackRock
New York
|
+$1.95M |
| 3 |
State Street
Boston,
Massachusetts
|
+$520K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$445K |
| 5 |
Renaissance Technologies
New York
|
+$445K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.2M |
| 2 |
SIM
Spark Investment Management
New York
|
-$394K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$371K |
| 4 |
Morgan Stanley
New York
|
-$247K |
| 5 |
First Manhattan
New York
|
-$223K |
YARW Hedge Fund Activity: Q2 2019 in Review
52 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q2 2019, worth a combined $110M — down 21% from $139M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new YARW positions and 5 closed out — a net gain of 1 holder — while 24 added to existing stakes and 7 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $2M. The largest seller was Great Point Partners, cutting an estimated $2.2M.
- 52 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q2 2019, down from 53 in Q1 2019.
- Funds reported $110M of Yarrow Bioscience, Inc. Common Stock stock for Q2 2019, down 21% quarter-over-quarter.
- 6 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q2 2019 and 5 closed out, a net change of +1 holder.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q2 2019 was Mangrove Partners, an estimated $2M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q2 2019 was Great Point Partners, an estimated $2.2M sold.
Based on aggregated 13F filings for Q2 2019.